Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

EraPerMed consortium on Personalized Medicine in Schizophrenia: predicting relapse, treatment response and the potential benefit of add-on anti-inflammatory agents

Projekt: Typer af projekter

  • Benros, Michael Eriksen (Projektleder, faglig)
  • Glaichenhaus, Nicolas , Frankrig (Projektleder, faglig)
  • Leboyer, Marion, Fondation FondaMental (Projektdeltager)
  • Hasan, Alkomiet, University of Augsburg, Tyskland (Projektleder, faglig)
Vis graf over relationer
Intro: Schizophrenia is a disabling mental illness that affects millions of Europeans. While antipsychotics alleviate symptoms in 1/3 of patients, majority of patients are refractory to treatment. Although guidelines are available, there is an urgent need to identify objective predictors of treatment outcome to guide personalized treatment.
Metoder: The Project will take advantage of clinical data and serum samples collected from three randomized, placebo-controlled, double-blind clinical trials which have been designed to evaluate the efficacy of anti-inflammatory agents as adjunct drugs in schizophrenia patients. It will also build on data and samples collected from outpatients followed yearly in the French Schizophrenia Expert Centres. In the first and second work packages (WP), a robust immunoassay will be used to quantitate serum levels of pertinent inflammation-related molecules. Using advanced supervised machine learning methods, predictive blood-based classifiers will be generated to identify patients at risk of non-responding to conventional antipsychotic monotherapy, patients at risk of relapse following treatment, and patients at risk of developing antipsychotic-induced adverse effects (predictive pharmacovigilance). In the remaining WPs, a randomized, double-blind phase III intervention study (WP3) will be conducted to validate the hypotheses and to model its cost-effectiveness when combined with a blood-based algorithm for selecting patients (WP4).
Resultater (forventede):
i) a subset of patients exhibiting a pro-inflammatory profile can benefit from add-on anti-inflammatory drugs,
(ii) blood levels of inflammatory immune molecules can predict treatment outcome (failure or response) in schizophrenia patients.
Diskussion/impact (forventet):
Identifying objective predictors of treatment outcome for psychosis can guide personalized treatment.
StatusIgangværende
Periode01/01/202131/12/2023

    Forskningsområder

  • Sundhedsvidenskab - Schizophrenia Spectrum and Other Psychotic Disorders, Biomarkers, Cognition, Genetic Techniques, Pharmacology, Physical Treatments, Meta-Analysis, Observational Study, Randomized Controlled Clinical Trial

ID: 61833709